ANGLE plc Completes Key Assay Developments and Eisai Contract

ANGLE plc ( (GB:AGL) ) has provided an announcement.

ANGLE plc announced the successful completion of assay development projects for AstraZeneca, including the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay. These assays are now approved for use and position ANGLE to conduct large-scale clinical trials, enhancing its market opportunities in the growing AR and DDR therapeutic markets. Additionally, ANGLE completed a Phase 2 pilot study with Eisai, demonstrating the Parsortix system’s ability to dynamically assess HER2 status in breast cancer patients, which could significantly impact HER2-ADC clinical trials. Despite Eisai not progressing with the BB-1701 drug, ANGLE maintains a strong relationship with them and is exploring further collaborations.

More about ANGLE plc

ANGLE plc is a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products through its Parsortix system, which is FDA cleared and used for complete downstream analysis of blood samples.

YTD Price Performance: -4.88%

Average Trading Volume: 1,401,673

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: £29.03M

Learn more about AGL stock on TipRanks’ Stock Analysis page.